Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11735212 | 0.95 | ALDH1A1 (0.33) | HTR6ALDH1A1 | |
| SCHEMBL31460120 | 0.74 | CYP2D6 (0.36) | HRH3ALDH1A1 | |
| SCHEMBL962787 | 0.70 | HTR6 (0.31) | HTR6CHRM5ADRA2CHRH3 | |
| SCHEMBL21160967 | 0.70 | HRH3 (0.36) | HRH3ALDH1A1 | |
| SCHEMBL1634908 | 0.70 | HTT (0.34) | HTR6CHRM5ADRA2CALDH1A1 | |
| SCHEMBL633803 | 0.70 | HRH3 (0.36) | HRH3ALDH1A1 | |
| SCHEMBL18768680 | 0.70 | HRH3 (0.36) | HRH3ALDH1A1 | |
| SCHEMBL7870406 | 0.70 | HTR6 (0.31) | HTR6CHRM5ADRA2CHRH3 | |
| SCHEMBL729174 | 0.70 | HTR6 (0.31) | HTR6CHRM5ADRA2CHRH3 | |
| SCHEMBL3833380 | 0.70 | PHGDH (0.32) | HTR6CHRM5ADRA2CHRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143427-B2 | Method for producing aminoacetylpyrrolidinecarbonitrile derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-2123636-B1 | METHOD FOR PRODUCING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100099892-A1 | METHOD FOR PRODUCING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE | KYORIN PHARMACEUTICAL CO. LTD | 2010-04-22 | — | — | US | disclosed |
| EP-2123636-A1 | METHOD FOR PRODUCING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099892-A1 | METHOD FOR PRODUCING AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE | DPP4, DPP7, DPP8 | HTR6 558/4885CHRM5 1391/4885ADRA2C 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.